A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 801–900 of 1,003
Cancer Immunotherapy – The Target is Precisely on The Cancer and Also Not
Koo, S., Wang, W. W., & Toh, H. C. (2018) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v47n9p381 · Cited by 17
Strategies to sensitize cancer cells to immunotherapy
George, A., Şahin, İ., Carneiro, B. A., Dizon, D. S., Safran, H. P., & El‐Deiry, W. S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1891817 · Cited by 17
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches
Huang, R., Bi, Z., Hu, S., Zhang, Q., Su, X., & Zhang, W. (2023) · Biomarker Research · doi:10.1186/s40364-023-00478-5 · Cited by 16
Shah, R. K., Cygan, E. E., Kozlik, T., Colina, A. S., & Zamora, A. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1301100 · Cited by 16
Oyama, K., Nakata, K., Abe, T., Hirotaka, K., Fujimori, N., Kiyotani, K., Iwamoto, C., Ikenaga, N., Morisaki, S., Umebayashi, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571182 · Cited by 16
Computational methods and data resources for predicting tumor neoantigens
Zhao, X., Wei, L., & Zhang, X. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf302 · Cited by 16
Verdegaal, E. M. E., & van der Burg, S. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01113 · Cited by 16
T Cell Receptor Engineered Lymphocytes for Cancer Therapy
Rollins, M. R., Spartz, E. J., & Stromnes, I. M. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.97 · Cited by 16
Dao, T., Klatt, M. G., Korontsvit, T., Mun, S. S., Guzman, S., Mattar, M. S., Zivanovic, O., Kyi, C., Socci, N. D., O'Cearbhaill, R. E., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02764-9 · Cited by 16
Morisaki, T., Morisaki, T., Kubo, M., Onishi, H., Hirano, T., Morisaki, S., Eto, M., Monji, K., Takeuchi, A., NAKAGAWA, S., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15213 · Cited by 16
Identification of the core regulators of the HLA I-peptide binding process
Zhang, Y., Xing, Z., Liu, C., Wang, S., Huang, T., Cai, Y., & Kong, X. (2017) · Scientific Reports · doi:10.1038/srep42768 · Cited by 16
Roufas, C., Georgakopoulos‐Soares, I., & Zaravinos, A. (2021) · NAR Cancer · doi:10.1093/narcan/zcab005 · Cited by 16
Role of Different Peptides for Cancer Immunotherapy
Luthra, R., Datta, S., & Roy, A. (2021) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-021-10289-7 · Cited by 16
Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases.
Zhao, F., He, X., Sun, J., Wu, D., Pan, M., Li, M., Wu, S., Zhang, R., Yan, C., & Dou, J. (2015) · Europe PMC (PubMed Central) · Cited by 16
Takeda, K., Kitaura, K., Suzuki, R., Owada, Y., Muto, S., Okabe, N., Hasegawa, T., Osugi, J., Hoshino, M., Tsunoda, T., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2152-x · Cited by 16
Zhang, X., Goedegebuure, S. P., Myers, N. B., Vickery, T. L., McLellan, M. D., Gao, F., Sturmoski, M., Chen, M. Y., Kim, S. W., Chen, I., et al. (2021) · medRxiv · doi:10.1101/2021.11.19.21266466 · Cited by 16
Self-citationHarari, A., Sarivalasis, A., de Jonge, K., Thierry, A., Huber, F., Boudousquié, C., Rossier, L., Orcurto, A., Imbimbo, M., Baumgaertner, P., et al. (2021) · Cancers · doi:10.3390/cancers13225801 · Cited by 15
Application of Nanotechnology in Therapeutic Cancer Vaccines
Guo, J., Tang, L., Li, K., Ma, Q., Luo, S., Cheng, R., & Liu, C. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200122 · Cited by 15
Qiu, J., Jiang, Y., Ye, N., Jin, G., Shi, H., & Qian, D. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05531-x · Cited by 15
Short Peptides as Powerful Arsenal for Smart Fighting Cancer
Bojarska, J., & Wolf, W. M. (2024) · Cancers · doi:10.3390/cancers16193254 · Cited by 15
Individualized Neoantigen-Directed Melanoma Therapy
Khaddour, K., & Buchbinder, E. I. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00920-4 · Cited by 15
Morisaki, S., Onishi, H., Morisaki, T., Kubo, M., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Tsujimura, K., Yoshimura, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565696 · Cited by 15
Cancer vaccines: advances, hurdles, and future directions
Vlachostergios, P. J. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002350 · Cited by 15
Is Personalized Medicine Here?
Carneiro, B. A., Costa, R. L. B., Taxter, T., Chandra, S., Chae, Y. K., Cristofanilli, M., & Giles, F. J. (2016) · PubMed · Cited by 15
Prophylactic Vaccines for Nonviral Cancers
Scott, B., Yarchoan, M. M., & Jaffee, E. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050558 · Cited by 15
Distinct features of dendritic cell-based immunotherapy as cancer vaccines
Lee, C., Lee, M., & Rhee, I. (2018) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2018.7.1.16 · Cited by 15
Tsukamoto, H., Kubota, K., Shichiku, A., Maekawa, M., Mano, N., Yagita∥, H., Ohta, S., & Tomioka, Y. (2019) · Immunology · doi:10.1111/imm.13095 · Cited by 15
Wei, B. M., Hanlon, D. J., Khalil, D., Han, P., Tatsuno, K., Sobolev, O., & Edelson, R. L. (2020) · The Yale Journal of Biology and Medicine · Cited by 15
Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer
Murahashi, M., Tsuruta, T., Yamada, K., Hijikata, Y., Ogata, H., Kishimoto, J., Yoshimura, S., Hikichi, T., Nakanishi, Y., & Tani, K. (2021) · Anticancer Research · doi:10.21873/anticanres.14907 · Cited by 15
Ichimiya, S., Fujimura, A., Masuda, M., Masuda, S., Yasumatsu, R., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Yew, P. Y., et al. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1973491 · Cited by 15
Kiessling, A., Ramanathan, K., Nilsson, O. B., Notari, L., Renken, S., Kiessling, R. W., Grönlund, H., & Wickström, S. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.866763 · Cited by 15
Raccosta, L., Marinozzi, M., Costantini, S., Maggioni, D., Ferreira, L. M., Corna, G., Zordan, P., Sorice, A., Farinello, D., Bianchessi, S., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05620-7 · Cited by 15
Kang, Y., Zhang, W., Yu, Q., Gao, L., Quan, J., Gu, F., Wu, Y., Tian, Y., Wu, Z., Shao, S., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03446-y · Cited by 15
Ke, Y., Xin, K., Tao, Y., Li, L., Chen, A., Shao, J., Zhu, J., Zhang, D., Cen, L., Chu, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202306889 · Cited by 15
Ye, T., Zhong, Z., Cappellesso, F., Deswarte, K., Chen, Y., Lauwers, H., Lombaerde, E. D., Gontsarik, M., Lienenklaus, S., Lysebetten, D. V., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122693 · Cited by 15
Next-Generation Sequencing of Lung Cancers
Devarakonda, S. H. K., Masood, A., & Govindan, R. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.008 · Cited by 15
Yazdani, M., Jaafari, M. R., Verdi, J., Alani, B., Noureddini, M., & Badiee, A. (2020) · Immunotherapy · doi:10.2217/imt-2019-0173 · Cited by 15
New Strategies for Therapeutic Cancer Vaccines
Qin, H., Sheng, J., Zhang, D., Zhang, X., Liu, L., Li, B., Li, G., & Zhang, Z. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520618666181109151835 · Cited by 15
Uslu, U., Erdmann, M., Wiesinger, M., Schuler, G., & Schuler‐Thurner, B. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.09.001 · Cited by 15
Advanced T and Natural Killer Cell Therapy for Glioblastoma
Yoon, W., & Chung, D. (2023) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2022.0267 · Cited by 14
Amaya-Ramírez, D., Martínez-Enriquez, L. C., & Parra-López, C. (2023) · Vaccines · doi:10.3390/vaccines11071174 · Cited by 14
Sueangoen, N., Grove, H., Chuangchot, N., Prasopsiri, J., Rungrotmongkol, T., Sanachai, K., Darai, N., Thongchot, S., Suriyaphol, P., Sa-nguanraksa, D., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03627-3 · Cited by 14
Huang, X., Zhu, X., Yang, H., Li, Q., Gai, L., Sui, X., Lü, H., & Feng, J. (2024) · Molecules · doi:10.3390/molecules29071462 · Cited by 14
de Graaf, J. F., Pesic, T., Spitzer, F. S., Oosterhuis, K., Camps, M. G. M., Zoutendijk, I., Teunisse, B., Zhu, W., Arakelian, T., Zondag, G. C. M., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200835 · Cited by 14
Human TCR repertoire in cancer
Chen, L., Hu, Y., Zheng, B., Luo, L., & Su, Z. (2024) · Cancer Medicine · doi:10.1002/cam4.70164 · Cited by 14
Arabiyat, S. (2024) · Springer eBooks · doi:10.1007/978-981-96-0397-8_10 · Cited by 14
Current progress in neoantigen-based dendritic cell vaccines for solid tumors
Li, Y., Abudureheman, A., & Xu, J. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0267 · Cited by 14
Maggi, E. C., & Montagna, C. (2015) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2015.10.005 · Cited by 14
Gong, Z., Chen, M., Miao, J., Han, C.-J., Zhong, Q., Gong, F., & Gao, X. (2022) · Journal of Immunology Research · doi:10.1155/2022/8802004 · Cited by 14
Barajas, A., Amengual-Rigo, P., Pons-Grífols, A., Ortiz, R., Carmona, O. G., Urrea, V., de la Iglesia, N., Blanco-Heredia, J., Souza, C. A., Varela, I., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04843-8 · Cited by 14
Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Garzia, I., Nocchi, L., Avalle, L., Troise, F., Leoni, G., Seclì, L., Antonucci, L., Cotugno, G., Allocca, S., Romano, G., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0609 · Cited by 14
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies
Braun, D. A., & Wu, C. J. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000257 · Cited by 14
Neoantigen prediction from genomic and transcriptomic data
Battaglia, S. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.10.003 · Cited by 14
DeVette, C. I., Gundlapalli, H., Lai, S.-C. A., McMurtrey, C., Hoover, A. R., Gurung, H. R., Chen, W. R., Welm, A. L., & Hildebrand, W. H. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1685300 · Cited by 14
Self-citationHan, K.-C., Park, D., Ju, S., Lee, Y. E., Heo, S., Kim, Y. A., Lee, J. E., Lee, Y., Park, K. H., Park, S.-H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62244-z · Cited by 14
Organized immune cell interactions within tumors sustain a productive T-cell response
Cardenas, M. A., Prokhnevska, N., & Kissick, H. T. (2020) · International Immunology · doi:10.1093/intimm/dxaa057 · Cited by 14
Fujii, S., Yamasaki, S., Hanada, K., Ueda, S., Kawamura, M., & Shimizu, K. (2021) · Cancer Science · doi:10.1111/cas.15259 · Cited by 14
Ng, A. W. R., Tan, P. J., Hoo, W. P. Y., Liew, D. S., Teo, M. Y. M., Siak, P. Y., Ng, S. M., Tan, E. W., Rahim, R. A., Lim, R. L. H., et al. (2018) · PeerJ · doi:10.7717/peerj.5056 · Cited by 14
Targeting Neoantigens for Personalised Immunotherapy
Pritchard, A. L. (2018) · BioDrugs · doi:10.1007/s40259-018-0267-4 · Cited by 14
An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-cancer Vaccines
Kohli, A. S., Sanyal, S., Kaushal, R. S., & Dwivedi, M. (2024) · Current Genomics · doi:10.2174/0113892029319505240821063238 · Cited by 13
Leveraging T cells for cancer immunotherapy
Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 13
An Update on the Relevance of Vaccine Research for the Treatment of Metastatic Melanoma
Dillman, R. O. (2017) · Melanoma Management · doi:10.2217/mmt-2017-0021 · Cited by 13
Functional genomics: paving the way for more successful cancer immunotherapy
Ajina, R., Zamalin, D., & Weiner, L. M. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely017 · Cited by 13
Potential association factors for developing effective peptide-based cancer vaccines
Jiang, C., Li, J., Zhang, W., Zhuang, Z., Liu, G., Hong, W., Li, B., Zhang, X., & Chao, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931612 · Cited by 13
A comprehensive analysis of gasdermin family gene as therapeutic targets in pan-cancer
Huo, C.-L., Deng, Y., & Zhen-gang, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-17100-7 · Cited by 13
Shen, Y., Yu, L., Xu, X., Yu, S., & Yu, Z. (2022) · Cancer Innovation · doi:10.1002/cai2.26 · Cited by 13
Zelba, H., McQueeney, A., Rabsteyn, A., Bartsch, O., Kyzirakos, C., Kayser, S., Harter, J., Latzer, P., Hadaschik, D., Battke, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10111882 · Cited by 13
Yu, Z., Wu, M., Huang, Y., Wang, Y., Chen, Y., Long, Q., Lin, Z., Xue, L., Ju, C., & Zhang, C. (2023) · Biomaterials Science · doi:10.1039/d2bm01549h · Cited by 13
Millar, D. G., Yang, S. Y. C., Sayad, A., Zhao, Q., Nguyen, L. T., Warner, K., Sangster, A. G., Nakatsugawa, M., Murata, K., Wang, B. X., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03413-7 · Cited by 13
Neoantigens: The Novel Precision Cancer Immunotherapy
Zhang, T., Kurban, E., & Wang, Z. (2023) · Biologics · doi:10.3390/biologics3040017 · Cited by 13
Dey, S., Devender, M., Rani, S., & Pandey, R. K. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.02.003 · Cited by 13
Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients
Balan, S., Finnigan, J. P., & Bhardwaj, N. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000251 · Cited by 13
TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines
Bullock, T. N. J. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.005 · Cited by 13
Kuehm, L. M., Wolf, K. J., Zahour, J., DiPaolo, R. J., & Teague, R. M. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02346-4 · Cited by 13
Stifter, K., Dekhtiarenko, I., Krieger, J., Tissot, A. C., Seufferlein, T. T. W., Wagner, M., & Schirmbeck, R. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.04.003 · Cited by 13
Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model
Peterson, M., Murphy, S. N., Lainson, J. C., Zhang, J., Shen, L., Diehnelt, C. W., & Johnston, S. A. (2020) · BMC Immunology · doi:10.1186/s12865-020-00350-3 · Cited by 13
Yang, Z., Wei, S., Deng, Y., Wang, Z., & Liu, L. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa076 · Cited by 13
Lazdun, Y., Si, H., Creasy, T. H., Ranade, K., Higgs, B. W., Streicher, K. L., & Durham, N. M. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1118 · Cited by 13
Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells
Sugiyarto, G., Prossor, D., Dadas, O., Arcia, D., Elliott, T. J., & James, E. (2020) · Immunotherapy Advances · doi:10.1093/immadv/ltaa001 · Cited by 13
Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival
Li, W., Amei, A., Bui, F., Norouzifar, S., Lu, L., & Wang, Z. (2021) · Cancers · doi:10.3390/cancers13122879 · Cited by 13
Harnessing Gene Fusion-Derived Neoantigens for ‘Cold’ Breast and Prostate Tumor Immunotherapy
Velaga, R., Koo, K. M., & Mainwaring, P. N. (2022) · Immunotherapy · doi:10.2217/imt-2022-0081 · Cited by 13
Lin, J., Liu, J., Hao, S., Lan, B., Zheng, X., Xiong, J., Zhang, Y., Gao, X., Chen, C., Chen, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022598 · Cited by 13
Rovida, A., Maccalli, C., Scarfò, L., Dellabona, P., Σταματόπουλος, Κ., & Ghia, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1632 · Cited by 13
Yu, Z., Liu, W., He, Y., Sun, M., Yu, J., Jiao, X., Han, Q., Tang, H., Zhang, B., Xian, Y., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01176-1 · Cited by 13
Dendritic Cell Immune Modulation via Polyphenol Membrane Coatings
Janes, M. E., Park, K. S., Gottlieb, A. P., Curreri, A. M., Adebowale, K., Kim, J., & Mitragotri, S. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c01575 · Cited by 12
From prediction to precision: how immunopeptidomics advances neoantigen discovery
Shapiro, I. E., & Bassani-Sternberg, M. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.02.003 · Cited by 12
Unmasking targets of antitumor immunity via high-throughput antigen profiling
Battaglia, S., & Muhitch, J. B. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.03.001 · Cited by 12
Neoantigens and NK Cells: “Trick or Treat” the Cancers?
Lv, D., Khawar, M. B., Liang, Z., Gao, Y. M., & Sun, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931862 · Cited by 12
Zheng, J., Meng, W., Chen, S., Cui, Z., Xian, X., Tian, J. H., Krysko, D. V., Li, B., & Zhang, W. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.024 · Cited by 12
Cellular therapy against public neoantigens
Armistead, P. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126116 · Cited by 12
Abidi, A., Gorris, M. A. J., Brennan, E., Jongmans, M. C. J., Weijers, D., Kuiper, R. P., de Voer, R. M., Hoogerbrugge, N., Schreibelt, G., & de Vries, I. J. M. (2021) · Cancers · doi:10.3390/cancers13102345 · Cited by 12
The soldiers needed to be awakened: Tumor-infiltrating immune cells
Yaping, W., Wang, Z., Zhuling, C., Li, R., Pengyu, F., Lili, G., Cheng, J., Bo, Z., Liu, L., Guangdong, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.988703 · Cited by 12
Chuang, H.-Y., Suen, C., Hwang, M., & Roffler, S. R. (2015) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv041 · Cited by 12
Immune evasion pathways and the design of dendritic cell-based cancer vaccines.
Hanks, B. A. (2016) · PubMed · Cited by 12
Phoon, Y. P., Tannenbaum, C. S., & Diaz-Montero, C. M. (2021) · Clinics in Plastic Surgery · doi:10.1016/j.cps.2021.06.005 · Cited by 12
Alrumaihi, F., Alromaihi, R. A., Kumar, V., & Anwar, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121056 · Cited by 11
Sisk, C. K., Turner, L. M., Meraj, S., & Yusuf, N. (2026) · Cells · doi:10.3390/cells15020099 · Cited by 11
Pandey, A., Rai, S. K., Ma, L., Higa, L., Khadka, V. S., Yang, H., & Deng, Y. (2026) · Advanced Science · doi:10.1002/advs.202518960 · Cited by 11
Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD
Chen, M., Zhang, X., Ming, Z., Lingyu, Feng, X., Han, Z., & An, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05103-z · Cited by 11
Fu, C., Wang, J., Ma, T., Yin, C., Zhou, L., Clausen, B. E., Mi, Q., & Jiang, A. (2024) · Vaccines · doi:10.3390/vaccines12050460 · Cited by 11
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.